This open-access article is distributed under Creative Commons licence CC-BY-NC 4.0. The human immunodeficiency virus (HIV) is an ongoing threat to the health and wellbeing of children worldwide. In 2013, 1.3 million women living with HIV gave birth. [1] A closer look at these figures shows that 85% of all pregnant women, worldwide, living with HIV, reside in sub-Saharan Africa. [1] Since implementation of the highly effective prevention of mother-to-child transmission (PMTCT) programme in 2004, the incidence of vertically infected infants has declined. Despite this progress, an estimated 12 000 children were newly infected with HIV owing to mother-tochild transmission in South Africa (SA) in 2016 alone. [2] By promoting early diagnosis and, when necessary, timeous initiation of antiretroviral therapy (ART), one can reduce mortality, disease progression and neurodevelopmental impairment in children infected by HIV. [3] Mother-to-child transmission of HIV can occur in utero, intrapartum and via breastfeeding. In April 2015, the SA PMTCT guidelines recommended that all infants should be tested for HIV infection at birth. [4] In 2016, the overall (all weight categories) transmission rate at birth was 1.1%. [5] In utero HIV transmission rates in very low-birthweight (VLBW) infants is largely unknown, and more so in the Eastern Cape. In 2017, 31% of all VLBW infants born at East London public sector hospitals were HIV exposed. [6] Knowledge concerning this group of infants is important, as VLBW infants are at increased risk of in utero HIV transmission. [7-10] We aimed to report the prevalence of HIV infection in infants weighing less than 1 500 g (VLBW infants) at birth and to describe the characteristics of those infants who had a positive HIV polymerase chain reaction (PCR) test. Methods This was a retrospective cross-sectional study performed at Frere Hospital, East London, and Cecilia Makiwane Hospital, Mdantsane, SA, during a two-year study period between 1 May 2016 and 31 April 2018. Both hospitals follow current national paediatric guidelines in testing all HIV-exposed infants for HIV infection at birth. The qualitative HIV PCR assay used for infant HIV testing was the Roche Cobas Ampliprep/Cobas TaqMan (CAP/CTM). VLBW infants, i.e. weighing <1 500 g at birth, born to women living with HIV, were included in the study. Infants <500 g were excluded from the study as they are not admitted to the nursery owing to poor viability. Information was extracted from neonatal and hospital records and entered into an Excel (Microsoft Corp., USA) database. Data captured included maternal information (age, current ART details such as regimen, number of months on ART in relation to delivery and HIV viral load) and infant details (birthweight, HIV PCR result and Ballard gestational score). Ethics approval was granted by the Walter Sisulu University (WSU) Human Research Ethics Committee (ref. no. 039/2018). The clinical governance of the two hospitals gave permission for implementation of the study protocol. As this was a retro...